Brokers Offer Predictions for AstraZeneca FY2026 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Erste Group Bank boosted their FY2026 earnings per share estimates for AstraZeneca in a report issued on Wednesday, March 4th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $10.48 per share for the year, up from their prior forecast of $10.34. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Erste Group Bank also issued estimates for AstraZeneca’s FY2027 earnings at $11.50 EPS.

Several other equities research analysts have also commented on AZN. Guggenheim restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Citigroup began coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Trading Down 1.6%

NASDAQ:AZN opened at $194.44 on Monday. AstraZeneca has a 1 year low of $122.48 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The stock has a fifty day moving average price of $146.71 and a two-hundred day moving average price of $106.62. The stock has a market capitalization of $301.56 billion, a price-to-earnings ratio of 64.60, a PEG ratio of 1.59 and a beta of 0.32.

Institutional Investors Weigh In On AstraZeneca

A number of large investors have recently added to or reduced their stakes in the business. Triumph Capital Management acquired a new position in AstraZeneca during the third quarter worth about $25,000. MV Capital Management Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. Bangor Savings Bank increased its stake in shares of AstraZeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $30,000. Finally, Rakuten Investment Management Inc. acquired a new position in shares of AstraZeneca during the 3rd quarter worth approximately $31,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be given a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. AstraZeneca’s payout ratio is currently 66.26%.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.